Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department

Launched by MEDICAL UNIVERSITY OF SILESIA · Feb 27, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether a specific probiotic called Lactobacillus plantarum 299v can help prevent Clostridium difficile infections (CDI) in patients who are hospitalized and receiving antibiotics, particularly those in the nephrology and transplantation department. CDI is a serious infection that can occur after antibiotic treatment, especially in patients who are on immunosuppressive drugs. To participate, you need to be an adult over 18 years old, receiving immunosuppressive therapy, and undergoing antibiotic treatment.

If you qualify, you'll be randomly placed into one of two groups. One group will take a daily capsule of the probiotic for three months, while the other group will receive a placebo, which is an inactive substance. During the study, your health will be monitored through interviews, physical exams, and lab tests to see how well the probiotic works in preventing CDI. The study is currently recruiting participants, and it’s open to everyone regardless of gender. Your participation could help improve care for patients at risk of CDI in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • over 18 years old
• • organ transplantation or receiving immunosuppressive drugs for any other reasons
• • antibiotics therapy
• Exclusion Criteria:
• • no consent to participate in the study